FORMULATION OF RECOMBINANT HUMAN LUNG SURFACTANT

拟议研究的目标是制定有效的 合成表面活性物质在婴幼儿呼吸系统疾病治疗中的应用 窘迫综合征(RDS)RDS是由以下因素引起的 肺表面活性物质在出生时，目前正在通过协助 有机械呼吸的新生儿，一种只有在 数量有限的医疗中心，而且一个可以严重 损害肺部。 天然肺表面活性物质补充剂治疗RDS 看起来很有效，但受到人类稀缺性的严格限制 除了磷脂之外，表面活性蛋白质也是关键 表面活性剂的组成。重组DNA的应用 分离和表达人类基因的技术 表面活性蛋白质应该提供无限量的 合成表面活性物质由重组蛋白和 纯磷脂。两种主要的表面活性蛋白质之一 (SP28-36)已被克隆并通过重组表达 DNA方法。我们在这里建议分离和表达该基因 对于剩余的人类表面活性蛋白SP17。

The objective of the proposed research is formulation of effective synthetic surfactant to be used in treatment of infant Respiratory Distress Syndrome (RDS). RDS is caused by inadequate levels of lung surfactant at birth, and is presently treated by assisting the newborn with mechanical respiration, a therapy available only at a limited number of medical centers, and one which can severely damage the lungs. Treatment of RDS using natural lung surfactant supplemets appears effective, but is strictly limited by the scarcity of human surfactant proteins, which in addition to phospholipids, are key components of surfactant. The application of recombinant DNA techniques to isolate and express the genes for the human surfactant proteins should provide unlimited quantities of synthetic surfactant formulated with recombinant proteins and pure phospholipids. One of the two major surfactant proteins (SP28-36) has already been cloned and expressed by recombinant DNA methods. We here propose to isolate and express the gene for the remaining human surfactant protein, SP17.